DMACDiaMedica Therapeutics Inc.
$8.01+17% 1Y
$8.01
$5.3352 weeks$9.39
DMAC in its own filings
Nothing in DMAC's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
146
Events found in the filings · across 427 filings · the record starts in 2018
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 10, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 4, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 11, 2026
- SEC comment-letter activity25 occurrences
- 2025-08-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jan 5, 2026On December 19, 2025 DiaMedica Therapeutics Inc. (the “Company”) Sold 1,501,000 common shares to a healthcare institution fund at a purchase price of $8.10 per share in a block transaction under its at-the-market offering program.Other event · Form 8-K
- Dec 18, 2025As previously announced, DiaMedica requested and completed an in-person pre-IND meeting with the FDA for a planned study evaluating DM199 in pre-eclampsia.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…